Pamela McNamara


Pamela McNamara



Pamela McNamara is a senior executive experienced in running technology products and services businesses. She has focused her P&L experience on development and the successful commercial launch of innovative technologies and products. Pam is a member of the Innovation Excellence Leadership (IXL) Center leadership team, working with IXL”s clients on capability-building, innovation and commercialization of technologies and products. With IXL Center, Pam is London Campus Director and Mentor on the faculty of the Hult International Business School’s Action Learn Programs.

Pam was CEO of Arthur D. Little, Inc. from 2001 to 2002, during which she restructured and refocused the company, achieved profitable turnarounds of its business units, and secured short term refinancing to enable the 2002 sale of its business units and assets. Defense, energy, chemicals and healthcare businesses were ADL’s strong businesses during Pam’s leadership tenure. Pam joined Arthur D. Little, Inc., in 1979 as a research associate while completing her Tufts studies, and held various positions in the firm, including Managing Director of its Global Health Care business.

More recently, Pam was President of Cambridge Consultants, a lab-based business, designing and developing breakthrough medical devices, wireless medical and defense products and technologies. She was CEO of CRF, Inc., a global leader of innovative electronic patient diary solutions, mobile software and data management services for clinical trials. During Pam’s 5-year leadership from 2003 through 2008, CRF Inc. achieved 40% compound annual growth, and was the first in its sector to achieve sustained profitability, demonstrating scalability.

Pam currently is a Trustee of SouthCoast Health System and Hospitals Group, and of Brookhaven at Lexington, a lifecare community. She serves as an Overseer for the Tufts University School of Engineering and a Corporation Member of Woods Hole Oceanographic Institution. She is a member of the CEO Collaborative Forum and of MIT’s Venture Mentoring Service. She has previously served as an independent or non-executive corporate director on the boards of Omrix Biopharmaceuticals (NASDAQ: OMRI) and GTC Biotherapeutics (NASDAQ: BTCB). She holds a Bachelor of Science degree in civil engineering from Tufts University.